Inovio Pharmaceuticals, Inc. - Common Stock (INO)
Frequently Asked Questions About Inovio Pharmaceuticals, Inc. - Common Stock (INO)
Does Inovio Pharmaceuticals have any partnerships?
Yes, Inovio Pharmaceuticals has established various partnerships and collaborations over the years to enhance its research capabilities and accelerate product development. Notably, the company has partnered with organizations such as the Coalition for Epidemic Preparedness Innovations (CEPI) to advance its vaccine candidates. Collaborations with academic institutions, government agencies, and other biotech firms further aid Inovio in bringing innovative therapies to market.
How can I invest in Inovio Pharmaceuticals?
Investing in Inovio Pharmaceuticals can be done through purchasing shares of its stock, which is traded on the Nasdaq stock exchange under the symbol INO. Potential investors can buy shares through any brokerage account or trading platform that offers access to U.S. stock markets. As with any investment, it’s advisable to perform thorough research and assess the company’s performance, industry position, and overall market conditions before investing.
How does Inovio Pharmaceuticals' vaccine technology work?
Inovio Pharmaceuticals' vaccine technology works by introducing a plasmid DNA construct that encodes for antigens associated with a specific pathogen or tumor. Once delivered into the body, cells take up the plasmid DNA and begin to produce the encoded antigens, prompting an immune response. This response not only includes the activation of T cells and antibodies but also leads to immunological memory, potentially offering long-term protection against infectious diseases or cancer recurrence.
How has Inovio responded to the COVID-19 pandemic?
Inovio Pharmaceuticals has actively responded to the COVID-19 pandemic by rapidly advancing the development of INO-4800, its DNA vaccine candidate. The company collaborated with global health organizations to facilitate clinical trials and gathered data to demonstrate the safety and immunity provided by the vaccine. Inovio's commitment to addressing the pandemic reflects its broader mission to develop innovative solutions for emerging infectious diseases.
What are Inovio Pharmaceuticals' main products?
Inovio Pharmaceuticals' main products include a pipeline of immunotherapies and vaccines aimed at treating various forms of cancer and infectious diseases. Notable candidates include INO-4800, a DNA vaccine for COVID-19, and VGX-3100, an investigational therapeutic for cervical dysplasia caused by HPV. The company continually advances its product offerings through clinical trials and research, seeking to bring innovative solutions to the market.
What are the company's financial standing and stock performance?
Inovio Pharmaceuticals is publicly traded on Nasdaq under the ticker symbol INO. The financial performance of the company can fluctuate based on market conditions, clinical trial results, and overall developments in the biotechnology sector. Investors typically monitor the company's funding status, cash reserves, clinical trial milestones, and revenue potential from pipeline products to assess its financial health and stock performance.
What challenges is Inovio Pharmaceuticals facing?
Like many biopharmaceutical companies, Inovio Pharmaceuticals faces several challenges, including the complexities of clinical development, regulatory hurdles, and competition from other companies developing similar technologies. Additionally, the financial sustainability of research and development efforts is a persistent concern, along with managing investor expectations. Navigating these challenges requires strong leadership, innovation, and strategic partnerships to succeed in the dynamic biotech landscape.
What clinical trials is Inovio Pharmaceuticals currently conducting?
Inovio Pharmaceuticals is actively conducting several clinical trials for its therapeutic and vaccine candidates across various disease areas. Some of the ongoing trials include those for VGX-3100 in treating cervical dysplasia and studies on INO-4800 for COVID-19. The company routinely updates its clinical trial statuses and results, providing transparency to stakeholders and the public about the progress and outcomes of its research.
What does Inovio Pharmaceuticals, Inc. do?
Inovio Pharmaceuticals, Inc. is a biopharmaceutical company that develops innovative DNA-based therapies for serious diseases. The company's primary focus is on the development of immunotherapies and vaccines, particularly in the areas of oncology and infectious diseases. Inovio's proprietary technology allows for the precise delivery of DNA plasmid, which prompts the body to create its own therapeutic proteins to combat various conditions. The company is recognized for its research in developing treatments for cancers, including prostate cancer and HPV-related cancers.
What is Inovio's approach to cancer treatment?
Inovio Pharmaceuticals' approach to cancer treatment primarily involves developing immunotherapies that activate the body's immune system to identify and destroy cancer cells. This includes the use of DNA-based vaccines that encode tumor antigens, inducing a targeted immune response. By harnessing the power of the immune system, Inovio aims to create effective therapeutic options for patients with various forms of cancer, potentially leading to durable responses and improved survival rates.
What is the company's long-term vision?
Inovio Pharmaceuticals' long-term vision is centered around transforming the treatment landscape for cancer and infectious diseases through innovative DNA-based therapies. The company aims to become a leader in the field of immunotherapy and vaccine development, enhancing patient outcomes and extending lives. Inovio is committed to scientific advancement, collaboration, and the continuous exploration of new therapeutic modalities to achieve this vision.
What is the significance of INO-4800?
INO-4800 is Inovio Pharmaceuticals' investigational DNA vaccine designed to prevent COVID-19. It has garnered significant attention due to its potential efficacy and safety profile, having entered various phases of clinical trials during the COVID-19 pandemic. INO-4800 represents a critical part of Inovio's response to global health challenges, illustrating the adaptability of their DNA platform in addressing urgent health crises.
What regulatory approvals has Inovio obtained?
Inovio Pharmaceuticals has achieved various regulatory milestones for its development programs, including fast-track designations and investigational new drug (IND) approvals from the U.S. Food and Drug Administration (FDA). However, as of now, the company has not yet received full marketing approvals for its therapeutic candidates. Regulatory approvals are crucial for advancing clinical trials and ultimately bringing therapies to market.
What role does electroporation play in Inovio's technologies?
Electroporation is a key technology utilized by Inovio Pharmaceuticals to enhance the delivery of DNA into cells. This process involves applying short electrical pulses to the target tissue, creating temporary pores in cell membranes through which the plasmid DNA can enter. The use of electroporation increases the efficiency of DNA delivery, enhancing the immune response and ultimately improving the efficacy of Inovio’s vaccines and therapies.
What technology does Inovio Pharmaceuticals utilize?
Inovio Pharmaceuticals utilizes a proprietary technology platform known as SynCon®, which is designed for the development of DNA-based therapies. This platform enables the precise delivery of plasmid DNA into cells using electroporation, a process that enhances the immune response by allowing cells to produce proteins associated with specific diseases. This technology is instrumental in the company’s vaccine and therapeutic pipeline, providing a unique approach to disease treatment.
When was Inovio Pharmaceuticals founded?
Inovio Pharmaceuticals was founded in 1979 and has since evolved to focus significantly on immunotherapy and DNA-based therapeutics. Originally established as a biotechnology startup, the company has gone through various phases of growth and development, particularly amplifying its research capabilities and technological advancements in the 2000s. Over the years, Inovio has gained recognition for its innovative approach to treating challenging diseases.
Where is Inovio Pharmaceuticals headquartered?
Inovio Pharmaceuticals is headquartered in Plymouth Meeting, Pennsylvania. This location serves as the central hub for the company’s operational, research, and administrative functions. The choice of Pennsylvania is strategic, given its proximity to leading research institutions and a vibrant biopharmaceutical community, fostering collaboration and innovation in the field.
Who are the key executives at Inovio Pharmaceuticals?
Inovio Pharmaceuticals is led by a team of experienced executives who bring extensive expertise in biotechnology and pharmaceutical development. The management includes leaders with backgrounds in clinical research, regulatory affairs, business development, and finance. The leadership team works collectively to drive the company's strategic vision, foster innovation, and ensure the successful development and commercialization of its products.
What is the current price of Inovio Pharmaceuticals, Inc. - Common Stock?
The current price of Inovio Pharmaceuticals, Inc. - Common Stock is 1.660
When was Inovio Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Inovio Pharmaceuticals, Inc. - Common Stock was at 4:00 pm EDT on April 2nd, 2025
What is the market capitalization of Inovio Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Inovio Pharmaceuticals, Inc. - Common Stock is 349.19M
How many shares of Inovio Pharmaceuticals, Inc. - Common Stock are outstanding?
Inovio Pharmaceuticals, Inc. - Common Stock has 210.36M shares outstanding.